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OBJECTIVES We sought to describe the incidence of late angiographic stent thrombosis (LAST) events in
an unselected drug-eluting stent (DES) population.
BACKGROUND Concerns have been raised that LAST may be a potential limitation of DES.
METHODS We have previously reported the angiographic incidence of early stent thrombosis (1.0%) in
this prospective cohort of 2,006 patients treated with either sirolimus-eluting stents (SES) (n
 1,017) or paclitaxel-eluting stents (PES) (n  989). We continued long-term follow-up to
determine the incidence of LAST events, defined as angiographically proven stent thrombosis
associated with acute symptoms more than 30 days after DES implantation. All patients had
at least 1 year of follow-up, mean duration 1.5 years.
RESULTS There were eight angiographically confirmed LAST events in seven patients: three with SES
(at 2, 25, and 26 months) and five with PES (at 6, 7, 8, 11, and 14.5 months). Three cases
were related to complete cessation of antiplatelet therapy, two cases occurred while patients
were on aspirin therapy within one month of cessation of clopidogrel, and three cases occurred
at a time when patients were apparently clinically stable on aspirin monotherapy. We
observed no cases of LAST in patients who were on dual antiplatelet therapy. Two deaths
occurred directly as a result of LAST.
CONCLUSIONS Angiographically proven late stent thrombosis occurs with an incidence of at least 0.35%
(95% confidence limits 0.17% to 0.72%) in patients treated with DES. Importantly, it may
also occur when patients are stable on antiplatelet monotherapy. (J Am Coll Cardiol 2005;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.08645:2088–92) © 2005 by the American College of Cardiology Foundation
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rrug-eluting stents (DES) have revolutionized the practice
f interventional cardiology with their proven efficacy in
educing restenosis rates. In the U.S., up to 80% of stent
mplantations currently are with DES. A meta-analysis of
1 randomized trials confirmed the efficacy and safety
rofile of these stents, but these trials were not powered to
etect or exclude an effect of DES on rare events such as
tent thrombosis (1). Since April 2002, we have adopted a
olicy of universal DES implantation for all patients irre-
pective of clinical presentation or angiographic features, the
all-comers” approach. Based on this approach, we were
ble to define the incidence of early stent thrombosis (30
ays) in a DES population of 2,006 patients (2).
Our institution has been confronted with patients pre-
enting with late angiographic stent thrombosis (LAST)
vents, an unexpected occurrence given the long period of
ual antiplatelet therapy prescribed in comparison to bare
tents (3). Late angiographic stent thrombosis events were
ncommon with bare stents except after brachytherapy (4),
nd subsequent to that report, dual antiplatelet therapy was
rolonged for that population. Furthermore, in animal
From the Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.
his study was supported by the Erasmus Medical Center, Rotterdam, and by
nrestricted institutional grants from Boston Scientific Corporation and Cordis, a
ohnson & Johnson company.n
Manuscript received January 25, 2005; revised manuscript received February 25,
005, accepted February 28, 2005.odels, DES may delay or cause incomplete healing to a
reater degree than with bare-metal stents (5). Therefore,
e sought to investigate the incidence of LAST events in
he DES population.
ETHODS
tudy design and patient population. Briefly, since April
002, we have adopted a policy of universal DES implan-
ation for all patients irrespective of clinical presentation or
ngiographic characteristics, known as an “all-comers pop-
lation.” We have previously reported on the incidence of
arly stent thrombosis (defined as stent thrombosis occur-
ing within the first 30 days following stent implantation) in
,006 consecutive patients after DES implantation (2). This
tudy population thus comprises 1,017 patients treated with
irolimus-eluting stents (SES) from April 2002 to February
003, and 989 patients treated with paclitaxel-eluting stents
PES) from February 2003 to December 2003. We contin-
ed a long-term (minimum one year) follow-up on this
ohort of patients to determine the incidence of LAST.
ollow-up. Post-discharge survival status was obtained
rom the Municipal Civil Registries. A health questionnaire
as sent to all living patients with specific questions on
e-hospitalization and adverse events. As the principal
eferral center within the region, repeat procedures are
ormally performed at our institution and recorded prospec-
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vent at another center, medical records or discharge summa-
ies from the other institutions were systematically reviewed.
eneral practitioners, referring cardiologists, and patients were
ontacted as necessary for additional information.
rocedure and antiplatelet management. All interven-
ions were performed according to current standard guide-
ines, with the interventional strategy including periproce-
ural glycoprotein IIb/IIIa inhibitor and intravascular
ltrasound (IVUS) use left to the discretion of the operator.
atients were pretreated with aspirin and a loading dose of
00 mg clopidogrel.
uration of clopidogrel therapy. Upon completion of the
ndex procedure, patients are advised to maintain lifelong
spirin therapy. Patients who received SES were prescribed
lopidogrel for three or six months depending on the
omplexity of the procedure, whereas patients treated with
ES were given a six-month prescription. In the Nether-
ands, clopidogrel after stenting is not reimbursed by med-
cal insurance companies and our department has covered
he cost for patients treated here. As a tertiary referral
enter, most of our patients are referred from other institu-
ions and after discharge from our institution, are managed
y referring physicians at peripheral centers. Late decisions
egarding antiplatelet therapy are at their discretion.
efinition of LAST. Late angiographic stent thrombosis
s defined as late—occurring at least one month after DES
mplantation with acute symptoms; angiographic—stent
hrombosis confirmed angiographically; stent thrombosis—
efined as Thrombolysis In Myocardial Infarction (TIMI)
ow 0 or 1 or the presence of flow-limiting thrombus
TIMI flow 1 or 2).
ESULTS
aseline and procedural characteristics. The average age
f our patients was 62 years, with 72% being male (Table 1).
ver half had multivessel disease on angiography, one-third
resented with unstable angina, and 22% with an acute
yocardial infarction (MI) as the indication for treatment.
tent type was approximately equally distributed as was the
nrolment period. On average, 1.9 lesions in 1.4 vessels were
reated with 2.3 stents implanted, totaling 43 mm/patient.
indings. Follow-up was complete for 98% of the popula-
ion. Mean follow-up was 1.5 0.5 years. There were eight
AST events in seven patients, three with SES and five
Abbreviations and Acronyms
DES  drug-eluting stents
IVUS  intravascular ultrasound
LAST  late angiographic stent thrombosis
MI  myocardial infarction
PES  paclitaxel-eluting stents
SES  sirolimus-eluting stents
TIMI  Thrombolysis In Myocardial Infarctionith PES (Tables 2 and 3), with an overall incidence of
l
s.35% (95% confidence limits 0.17% to 0.72%). All patients
ere male, and all presented at the time of LAST with an
cute ST-segment elevation MI. Figure 1 is a representative
xample of LAST. No differences in patient characteristics
Table 1) were noted between patients with and without
AST. None of the 20 patients described in the previous
eport with early stent thrombosis (2) developed LAST.
There were two deaths in the seven patients with LAST.
ne death (Patient #6) occurred in a patient who received
SES to the left anterior descending coronary artery
LAD). Late angiographic stent thrombosis 25 months later
esulted in a large anterior MI with cardiogenic shock and
he patient died from refractory left ventricular failure two
ays later. The second death occurred in a patient (Patient
7) who had a pre-existing occlusion of the right coronary
rtery that received collaterals from the LAD. A single SES
as implanted at a proximal LAD lesion. Late angiographic
tent thrombosis 26 months later resulted in a large acute
nterior MI with cardiogenic shock and the patient died on
he catheterization table. Of note, in both these patients,
nitial attempts to pass a wire through the previous stent
ere unsuccessful because the wires, on each occasion,
ppeared to pass between the outside of the stent and the
able 1. Baseline and Procedural Characteristics of
rug-Eluting Population
Drug-Eluting Stents
(n  2,006)
aseline characteristics
Age, yrs, mean  SD 61.9  11.3
Male, % 72
Diabetes, % 17
Hypercholesterolemia, % 58
Current smoker, % 28
Hypertension, % 41
Previous myocardial infarction, % 33
Previous PCI, % 25
Previous CABG, % 9
Multivessel disease, % 57
ndication for index procedure
Stable angina, % 42
Unstable angina, % 33
Acute myocardial infarction, % 22
Silent ischemia, % 3
rocedural characteristics
Number of lesions treated, mean  SD 1.9  1.0
Number of vessels treated, mean  SD 1.4  0.6
LAD, n 1,135
LCx, n 665
RCA, n 784
Others, n 163
Patients treated with SES, n 1,017
Patients treated with PES, n 989
Total stented length, mm (mean  SD) 43  31
Number of stents implanted, n (mean  SD) 2.3  1.5
At least one 2.50 mm stent implanted (%) 38
Bifurcations stented, % 18
Glycoprotein IIb/IIIa use (%) 25
ABG  coronary artery bypass grafting; LAD  left anterior descending; LCx 
eft circumflex; PCI  percutaneous coronary intervention; PES  paclitaxel-eluting
tent; RCA  right coronary artery; SES  sirolimus-eluting stent.
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Late Stent Thrombosis With Drug-Eluting Stents June 21, 2005:2088–92essel wall. This is highly suggestive of acquired aneurysm
ormation at the stented site because on review, the initial
rocedural result was optimal. Due to hemodynamic insta-
ility, IVUS was not attempted. Autopsy was refused in
oth cases.
One patient (Patient #3) treated with a PES to the LAD
eveloped two LAST events. The first occurred 11 months
fter the index procedure and re-presented with an anterior
T-segment elevation MI. He was treated with a new PES
nside the original PES stent and lifelong clopidogrel was
ecommended; before discharge he was given his first
rescription of six months worth of clopidogrel. He com-
leted the prescribed six-month course of dual antiplatelet
herapy and did not renew the prescription of clopidogrel.
wenty-one days later, he re-presented with lateral ST-
egment elevation. Three new PES were used to re-canalize
diagonal branch occluded with thrombus. Intravascular
ltrasound study did not reveal a specific contributory
actor, in particular, there was no evidence of incomplete
tent apposition.
With regard to antiplatelet therapy, three events occurred
hen patients had stopped all antiplatelet therapy (two were
or non-cardiac surgery, and one due to non-compliance).
ive events occurred in patients on aspirin monotherapy
ho had completed their prescribed course of clopidogrel.
wo of these events occurred soon after (21 and 28 days)
lopidogrel was stopped.
reatment. Balloon angioplasty was performed in all pa-
ients, followed by new DES implantation in seven of eight
Table 3). Glycoprotein IIb/IIIa inhibitors were used in five
ases. Intravascular ultrasound was performed in two pa-
ients with no evidence of incomplete stent apposition
oted. A thrombectomy device was used in two cases. After
n episode of late stent thrombosis, prolonged clopidogrel
herapy was empirically recommended.
ISCUSSION
he purpose of this report is to highlight that LAST occurs
ith an incidence of at least 0.35% and possibly up to 0.72%
fter DES implantation. Furthermore, we have now ob-
erved that LAST may also occur not only in temporal
elation to complete cessation of antiplatelet therapy (3), but
ay also occur shortly after clopidogrel is stopped but
spirin continued, and unexpectedly remote from clopi-
ogrel cessation when patients were clinically stable on
ong-term aspirin therapy. We observed no episodes of
AST while patients were on dual antiplatelet therapy.
In the randomized trials of DES, late stent thrombosis
as been reported. Two presumed late stent thromboses
elated to clopidogrel discontinuation were reported in the
AXUS-II trial (6). With SES, there has been one pub-
ished report of LAST from the European multicenter,
andomized, double-blind study of the SIRolImUS-coated
x velocity balloon-expandable stent in the treatment ofpatients with de novo coronary artery lesions (E-SIRIUS)Ta
b
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June 21, 2005:2088–92 Late Stent Thrombosis With Drug-Eluting Stentsrial, with accompanying histological findings showing ac-
uired aneurysm formation with eosinophilic infiltrates; the
nvestigators concluded that LAST was due to a hypersen-
itive reaction to the polymer coating of the stent (7). Two
f the LAST events we report occurred more than two years
fter SES implantation and both patients died. The timing
f the events and the intraprocedural difficulty in wiring the
esion in both patients are potentially compatible with a
imilar etiology of LAST.
Late stent thrombosis was a major problem with the now
iscontinued QP2 stent program (8). The ongoing occur-
ence of stent thrombosis (3.2%, 7.1%, and 10.3% at 1, 6,
nd 12 months) in the Study to COmpare REstenosis Rate
etween QueST and QuaDDS-QP2 (SCORE) trial was
ttributed to the long duration of high-dose drug release
nd proinflammatory nature of the polymer sleeves.
Several mechanisms of LAST have been postulated: a
ocal drug effect delaying endothelialization or results in the
ormation of a dysfunctional endothelium, a hypersensitiv-
ty, or inflammatory reaction to the polymer, or the devel-
pment of neointimal hyperplasia with occlusive thrombus
ormation as the acute event. Furthermore, it is known that
revious treatment with brachytherapy is associated with an
ncreased risk of late stent thrombosis when on mono-
ntiplatelet therapy (4); however, no patient in this report
ad previous brachytherapy in the stented segment. The use
f IVUS, if clinically feasible at the time of stent thrombo-
is, may help facilitate the elucidation of its etiology.
able 3. Treatment of Patients With LAST
Pt.
No. Age, Gender IVUS
Glycoprotein
IIb/IIIa Use
1 74, Male No Abciximab Balloon angioplas
2 57, Male Yes Abciximab Thrombectomy, b
3a 64, Male* Yes Abicixmab Balloon angioplas
3b 64, Male* No Abciximab Balloon angioplas
4 74, Male No No Thrombectomy, b
5 39, Male No No Balloon angioplas
6 63, Male No Integrellin Balloon angioplas
inotropes
7 71, Male No No Balloon angioplas
aortic balloon p
This patient had two separate episodes of late stent thrombosis.
IVUS  intravascular ultrasound; other abbreviations as in Tables 1 and 2.igure 1. Representative film of late angiographic stent thrombosis (LAST). (A
ngiographic stent thrombosis with ST-segment elevation. (C) After wire passaowever, their clinical condition often precludes a pre-
ntervention IVUS.
In patients with documented LAST, we empirically
rescribe long-term dual antiplatelet therapy in an attempt
o reduce recurrence. The use of long-term dual antiplatelet
herapy for the primary prevention of LAST is more
roblematic. Although it would seem intuitive to do so,
here is debate in published literature. There are data from
he pre-DES era to suggest that in selected patients,
rolonged dual antiplatelet therapy is associated with a
eduction in major adverse cardiac events (9,10); however,
uch potent inhibition of platelet function is associated with
n increased risk of major bleeding complications (11,12).
It is difficult to compare the incidence we have reported
ith that from the bare stent era due to the paucity of
eports; a single center registry reported a late stent throm-
osis incidence (defined as 30 days) of 0.76%, a figure not
issimilar to this report (13).
The results of this preliminary report expand our previous
bservations that LAST occurs with DES, demonstrate that
t may occur when patients are receiving antiplatelet mono-
herapy, and provide an estimate of the expected rate in an
nselected DES population. Its incidence is low, but po-
entially problematic given the rapid uptake of such stents.
t is imperative that cardiologists and other doctors who
reat these patients are aware of this potential late compli-
ation, and any decision to stop antiplatelet therapy for
hatever reason must take this into account.
Treatment
Post-LAST Clopidogrel
Recommendation
S 2.75*18 mm Lifelong
n angioplasty, PES 3.5*20 mm 1 year
S 2.25*8mm, 3.5*8 mm, 3.5*8 mm Lifelong
S 3*32 mm Lifelong
n angioplasty, PES 3.5*12 mm Not stated
otropes, atropine Not stated
S 2.5*24 mm, intra-aortic balloon pump, —
S 3*20 mm, 3*8 mm, 3*12 mm, intra-
, inotropes
—ty, SE
alloo
ty, PE
ty, PE
alloo
ty, in
ty, PE
ty, PE
ump) Index procedure, post-stent implantation, right coronary artery. (B) Late
ge, LAST demonstrating large thrombus burden.
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Late Stent Thrombosis With Drug-Eluting Stents June 21, 2005:2088–92tudy limitations. This report is confined to patients who
resented with acute symptoms and angiographically proven
ate stent thrombosis. The low frequency of postmortem
tudies performed in the Netherlands, which would have
ccurately determined the cause of death, precluded an
ccurate assessment of the overall rate of late stent
hrombosis.
eprint requests and correspondence: Prof. Patrick W. Serruys,
horaxcenter, Ba-583, Dr. Molewaterplein 40, 3015-GD Rotter-
am, the Netherlands. E-mail: p.w.j.c.serruys@erasmusmc.nl.
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